15/06/2025 00:20 Off-Road & Electric: Chevy Brings Trail Boss Trim to 2026 Silverado EV
15/06/2025 00:20 White House Instructs USDOT to Ignore GAO Opinion on Frozen EV Charger Funds
15/06/2025 00:20 DJI Rolls Out New Flagship Drone: the Matrice 400
14/06/2025 22:20 Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results
14/06/2025 22:20 Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC
14/06/2025 22:20 Jacobson Pharma Announces FY2025 Annual Results
14/06/2025 20:20 Israel, Iran resume missile exchange, threaten more attacks
14/06/2025 20:20 Bonnaroo Music & Arts Festival canceled due to weather
14/06/2025 20:20 Morgan Wallen’s ‘I Am the Problem’ tops U.S. album chart
14/06/2025 15:19 Lion Works Digital Launches New HIPAA-Compliant Marketing Package for Addiction Treatment Centers

Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

Home » News » Europe » Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

Tyisha Fetzer 10/06/2025 02:22

HONG KONG, Jun 9, 2025 – (ACN Newswire) – At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN…

ACN Newswire
HONG KONG, Jun 9, 2025 – (ACN Newswire) – At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN…
Read More

Pet Vet Products Unveils Vet-Formulated Chewable Supplements for Dogs: Calming, Joint Support, Allergy Relief & Daily Health

14/06/2025 Pet Vet Products

PetVet Products, founded by seasoned veterinarian Dr. Leah Hill, proudly announces the launch of a new line of functional dog

29,260 students enroll for 2025 TVET exams into federal technical colleges – NABTEB

14/06/2025 Enahoro Iyemefokhai

No fewer than 29,260 students enrolled for the 2025 nationwide Technical and Vocational Education and Training examination, TVET, into Federal

3 Things To Keep An Eye On In The 2nd Half Of “Our Unwritten Seoul”

14/06/2025 sollerina28

tvN’s drama “Our Unwritten Seoul” has shared three key points to look forward to as it enters the second half

Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

Pet Vet Products Unveils Vet-Formulated Chewable Supplements for Dogs: Calming, Joint Support, Allergy Relief & Daily Health

29,260 students enroll for 2025 TVET exams into federal technical colleges – NABTEB

3 Things To Keep An Eye On In The 2nd Half Of “Our Unwritten Seoul”

Services

About

This website uses cookies to ensure you get the best experience on our website.